Current Management of Early to Relapsing Forms of Multiple Sclerosis: A Comprehensive Approach
June 20, 2019
July 25, 2020
Scroll to the Bottom of this Information to Begin this Course
This activity is jointly provided by Consortium of Multiple Sclerosis Centers and PlatformQ Health Education, LLC.
Supported by an educational grants from Biogen, Celgene, Genentech, and Sanofi Genzyme.
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)™
- Nurses — maximum of 1.0 Continuing Nursing Education Credit (1.0 credits in the area of pharmacology).
All other health care professionals completing this course will be issued a statement of participation.
Neurologists, primary care physicians, advanced practice clinicians, nursing professionals, physician assistants, pharmacists and other HCPs involved in the care of patients with MS.
Upon completion of this activity, participants should be able to:
- Incorporate accumulated clinical evidence, current guidelines, and emerging new clinical data into individualized selection of DMTs for MS as part of a comprehensive approach to management that includes SDM with patients, ongoing monitoring, and DMT optimization
- Recognize the need to identify and address symptoms experienced by patients with MS, with attention to patients’ values and goals for treatment, and with appropriate selection of symptomatic interventions
- Take a multidisciplinary approach to diagnosing and addressing psychological and cognitive issues in patients with MS, including identification of sources of psychosocial support and wellness interventions
Physician Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Consortium of Multiple Sclerosis Centers (CMSC), and Platform Q Health Education. CMSC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Credit Designation
The CMSC designates this live activity for a maximum of AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The CMSC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Pharmacists Credit Designation Statement
The Consortium of Multiple Sclerosis Centers (CMSC) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education and will award 1.0 contact hours (.1 CEUs) to pharmacists who (1) complete the activity, (2) submit a passing post-test, and (3) complete the evaluation form. The Universal Activity Number (UAN) for this activity is JA4008165-9999-19-004-L01-P. This is a knowledge-based activity.
Upon successful completion of the activity, your CE credits will be submitted electronically to the NABP CPE Monitor service. For information about CPE Monitor, visit https://nabp.pharmacy/cpe-monitor-service/
Paper certificates are not valid for pharmacy credit.
Nursing Credit Designation Statement
The CMSC designates this live activity for a maximum of 1.0 Continuing Nursing Education Credit (1.0 credits in the area of pharmacology).
The CMSC designates this enduring material for a maximum of 1.0 Continuing Nursing Education Credit (1.0 credits in the area of pharmacology).
Certificate of Completion
A Certificate of Completion may be given upon completion of course requirements enabling you to register your credit with the appropriate licensing boards or associations. You may apply for other accreditations using the procedure established by the specific organization.
Disclosure of Financial Relationships
It is the policy of CMSC and Platform Q Health Education to ensure balance, independence, objectivity, and scientific rigor in all educational activities. All faculty, activity planners, content reviewers, and staff participating in this activity have disclosed any relevant financial relationships they or their spouse/life partner have within the previous 12 months with manufacturers of any commercial products/devices and/or providers of commercial services included in this educational activity. The intent of this disclosure is not to prevent a person with a relevant financial relationship from participating in the activity, but rather to provide participants with information on which they can base their own judgments. All presentations were reviewed by an independent clinician with no relevant financial relationships for the purpose of resolution of any identified conflict of interest and a determination of evidence-base and fair balance.
Disclosures of Conflicts of Interest
The faculty reported the following financial relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:
Scott D. Newsome, DO, MSCS, FAAN served as faculty for this activity. He has received consulting fees from Biogen, Genentech, Celgene, EMD Serono, Gerson Lehrman Group, and is a Clinical Adjudication Committee Member for a medDay Pharmaceuticals clinical trial. He is Principal Investigator for Biogen and Genentech clinical trials (paid directly to institution).
Robert K. Shin, MD, FANA, FAAN served as faculty for this activity. He has received consulting fees from Biogen, EMD Serono, Mallinckrodt, Novartis, and Sanofi Genzyme. He has served on the speaker’s bureau for Biogen, EMD Serono, Mallinckrodt, Novartis, and Sanofi Genzyme.
Amy Perrin Ross, APN, MSN, CNRN, MSCN served as faculty for this activity. She has received consulting fees from Biogen, EMD Serono, Novartis, Celgene, TG Therapeutics, Genzyme, and Genentech. She has served on the speaker’s bureau for Biogen, EMD Serono, Novartis, Teva, Genzyme, and Genentech.
June Halper, MSN, APN-C, MSCN, FAAN, served as planner and reviewer for this activity. She has disclosed no relevant financial relationships.
Laurie Scudder, DNP, NP, served as nurse planner and reviewer for this activity. She has disclosed no relevant financial relationships.
All other CMSC and Platform Q Health Education staff who are in a position to influence content have disclosed no relevant financial relationships.
Disclosure of Unlabeled Use
CMSC and Platform Q Health Education require faculty to disclose to the attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
Course Viewing Requirements
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
There are no fees to participate in this activity. To participate in the activity, go to https://cmscscholar.org or www.NeuroSeriesLive.com. To receive credit, participants must (1) read the activity front matter, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.
If you have questions about this CME/CNE activity, please contact the CMSC at email@example.com or 201-487-1050.
Information we collect is primarily used to communicate with program participants, award CME/CE credits, manage user accounts, recommend relevant programs and perform data analysis to inform educational outcomes.
In plain English, here is what we affirm:
- You can change your registration profile at any time from our “Profile” page
- To request any of these changes without logging in, please call us at 1 (877) 394-1306 or email us at support@PlatformQHealth.com
- You can end your association with PlatformQ Health at any time
- PlatformQ Health does not spam, nor we do we rent or sell our email list in whole or in part. Any program-related data sharing is for engagement verification and opt-in based further education
- EU citizens can request a complete record of their account and/or request to have their personal data expunged by contacting firstname.lastname@example.org with the subject line “Data Request”